Reversal for acquired resistance to EGFR inhibitors in lung cancer

doi:10.3760/cma.j.issn.1673-422X.2013.11.013

Abstract

Abstract: Epidermal growth factor receptor (EGFR) inhibitors targeted therapy is the forward position means for nonsmall cell lung cancer. However, acquired resistance to EGFR inhibitors limits the development of targeted drugs. Using existing data on drug resistance in EGFRmutant lung cancer, this review discusses three basic approaches for overcoming resistance to EGFRtargeted therapies: intensification of EGFR inhibition, combination of EGFR inhibitors with other targeted therapies, and altering clinical management via alternate pathways.

Key words: Lung neoplasms, Receptor, epidermal growth factor, Drug resistance, Inhibitors

LI Chen-Chen, FENG Ji-Feng. Reversal for acquired resistance to EGFR inhibitors in lung cancer[J]. Journal of International Oncology, 2013, 40(11): 843-846.

References

［1］ Heist RS, Christiani D. EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics, 2009, 10(1):59-68. ［2］ Oxnard GR, Arcila ME, Chmielecki J, et al. New strategies in overcoming acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer. Clin Cancer Res, 2011, 17(17):5530-5537. ［3］ Oxnard GR. Strategies for overcoming acquired resistance to epidermal growth factor receptortargeted therapies in lung cancer. Arch Pathol Lab Med, 2012, 136(10):1205-1209. ［4］ Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol, 2011, 29(15):2121-2127. ［5］ Onitsuka T, Uramoto H, Nose N, et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET and HGF status. Lung Cancer, 2010, 68(2): 198-203. ［6］乔建兵，陈文萍. 酪氨酸激酶抑制剂耐药机制及其治疗策略. 中国肺癌杂志, 2011, 14(10):806-810. ［7］ GodinHeymann N, Ulkus L, Brannigan BW, et al. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther, 2008, 7(4):874-879. ［8］ Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA, 2008, 105(6):2070-2075. ［9］ Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib,gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol, 2012, 13(5):528-538. ［10］ Zhou W, Ercan D, Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature, 2009, 462(7276):1070-1074. ［11］ Janjigian YY, Groen HJM, Horn L, et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol, 2011, 29(15 Suppl):7525. ［12］ Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 2011, 3(75):75ra26. ［13］ Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med, 2008, 14(12):1351- 1356. ［14］ Chaft JE, Arcila ME, Paik PK, et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinomarationale for comprehensive mutation profiling. Mol Cancer Ther, 2012, 11(2):485-491. ［15］ Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistanceto EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res, 2013, 19(8):2240-2247. ［16］尹威民，王旭，于明霞，等. 肺癌EGFR突变的TKI靶向治疗耐药机制研究进展. 中国老年学杂志, 2011, 31(11): 2136-2138. ［17］ Choi Y, Rho J, Jeon BS, et al. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors. Cancer Chemother Pharmacol, 2010, 66(2):381-388. ［18］ Wu JY, Shih JY, Yang CH, et al. Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer. Int J Cancer, 2010, 126(1):247-255. ［19］ Shimamura T, Li D, Ji H, et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res, 2008, 68(14):5827-5838. ［20］ Bivona TG, Hieronymus H, Parker J, et al. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature, 2011, 471(7339):523-526. ［21］ Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol, 2011, 29(22):2972-2977. ［22］ Chmielecki J, Foo J, Oxnard GR, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med, 2011, 3(90):90ra59. ［23］ Chaft JE, Oxnard GR, Sima CS, et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib. Clin Cancer Res, 2011, 17(19):6298-6303. ［24］ Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistanceto EGFR tyrosine kinase inhibitors in EGFR-mutantlung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res, 2011, 17(6):1616-1622.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[5]	Xie Shuping, Sun Yahong, Wang Chao. Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 157-165.
[6]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[7]	He Jiahui, Hu Qinyong. Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data [J]. Journal of International Oncology, 2024, 51(1): 29-36.
[8]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[9]	Chen Xinyi, Weng Yiming, Wei Jiayan, Wang Jinsong, Peng Min. Advances in immune checkpoint inhibitors in the treatment of recurrent or metastatic head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 553-557.
[10]	Deng Juanjun, Zhao Dayong, Li Miao. Adverse reactions and risk factors of immune checkpoint inhibitors in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2023, 50(9): 564-568.
[11]	Huang Hui, Ding Jianghua. Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma [J]. Journal of International Oncology, 2023, 50(9): 569-573.
[12]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying. Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2023, 50(8): 475-483.
[13]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui. Research progress of Nrf2 in ovarian cancer [J]. Journal of International Oncology, 2023, 50(8): 493-497.
[14]	Guo Ciliang, Jiang Chunping, Wu Junhua. Gut microbiome and tumor immunotherapy [J]. Journal of International Oncology, 2023, 50(7): 432-436.
[15]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.